Scarica l'app Stockscreener
19.40
0.41%
0.08
Dopo l'orario di chiusura:
19.31
-0.09
-0.46%
Panoramica
Notizia
Cronologia dei prezzi
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Crescent Biopharma Inc Borsa (CBIO) Ultime notizie
Corcept Therapeutics (NASDAQ:CORT) vs. Crescent Biopharma (NASDAQ:CBIO) Head to Head Review - Defense World
Crescent Biopharma Stock On Fire: Up 86% With 7-Day Winning Streak - Trefis
Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree - Trefis
Crescent Biopharma Stock Surges 85%, With A 6-Day Winning Spree - Trefis
Crescent Biopharma Stock Rockets 85% With 6-Day Winning Streak - Trefis
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above 200-Day Moving AverageTime to Sell? - MarketBeat
Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewswire
Three new Crescent Biopharma hires get stock options at $13.50 - Stock Titan
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Crescent Biopharma, Inc. (CBIO) Fundamental Analysis - meyka.com
Why Is Crescent Biopharma, Inc. (CBIO) Stock Down Today? - Meyka
Crescent Biopharma, Inc.: Fundamental Analysis and Financial Ratings | | US38000Q2012 - marketscreener.com
CBIO PE Ratio & Valuation, Is CBIO Overvalued - Intellectia AI
Crescent Biopharma (NASDAQ: CBIO) registers 19.58M resale shares from private placement - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Upgraded to Hold at Wall Street Zen - MarketBeat
HC Wainwright Has Optimistic Outlook of CBIO Q1 Earnings - Defense World
HC Wainwright Issues Optimistic Estimate for CBIO Earnings - MarketBeat
GLYC SEC FilingsGlycomimetics 10-K, 10-Q, 8-K Forms - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Given New $22.00 Price Target at HC Wainwright - Defense World
Crescent Biopharma (NASDAQ: CBIO) registers 19.58M resale shares after $185M placement - Stock Titan
CBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Price Target Lowered to $22.00 at HC Wainwright - MarketBeat
H.C. Wainwright cuts Crescent Biopharma stock price target to $22 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Crescent Biopharma stock price target to $22 - Investing.com Australia
Crescent BiopharmaFinancial Details - Crunchbase
A Look At Sichuan Kelun-Biotech Biopharmaceutical’s Valuation After The Crescent Biopharma Oncology Partnership - simplywall.st
Guggenheim Remains a Buy on Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma (CBIO) Posts US$10.8m Q4 Revenue Against Heavy Losses Challenging Bullish Narratives - simplywall.st
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Crescent Biopharma (CBIO) - The Globe and Mail
Stifel cuts Crescent Biopharma stock price target on equity financing - Investing.com South Africa
Stifel cuts Crescent Biopharma stock price target on equity financing By Investing.com - Investing.com Canada
Crescent Biopharma: Q4 Earnings Snapshot - theheraldreview.com
Crescent Biopharma Inc recently disclosed that certain revenues recognized in its 2025 financial report actually originate from a $20 million upfront payment made by Kelun-Biotech under a licensing agreement between the two parties for the core asset Cr-00 - Bitget
CBIO: Expanded oncology pipeline and strong cash position support multiple clinical milestones into 2028 - TradingView
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent ... - Bluefield Daily Telegraph
Crescent Biopharma (Nasdaq: CBIO) ramps R&D with $185M raise and 2025 loss - Stock Titan
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Crescent Biopharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Crescent Biopharma (NASDAQ:CBIO) Stock Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Crescent Biopharma: Fourth Quarter Financial Results Overview - Bitget
Crescent Biopharma to Present at March Investor Conferences - Bitget
Cancer-focused biotech Crescent Biopharma plans March investor talks in Boston and Miami - Stock Titan
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors - ADVFN
Crescent Biopharma announces grants of inducement awards - TipRanks
New hires at Crescent Biopharma get 10-year stock options - Stock Titan
Crescent Biopharma doses first patient in ASCEND cancer trial - Investing.com Nigeria
Should I Buy CBIO? CBIO 2026 AnalysisIntellectia AI™ - Intellectia AI
Crescent Biopharma announces first patient dosed in Ascend Phase 1/2 clinical trial of CR-001 - marketscreener.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):